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Bullous pemphigoid (BP) is the most common type of autoimmune bullous 
diseases; drug-induced bullous pemphigoid is a rare variant of it. In the last decade, 
there is an increasing prevalence of BP, especially dipeptidyl peptidase-4 inhibitor-
associated BP (DPP-4i-BP), with the higher prevalence of BP in diabetic patients. 
Recently, several clinical phenotypes of BP were detected, but there is a tendency 
in BP cases related to DPP-4 inhibitors to show an atypical noninflammatory form 
with less distributed skin symptoms, mild erythema, decreased eosinophilic infil-
tration in the periblister area, and normal or slightly elevated peripheral eosinophil 
count. Anti-NC16A BP180 autoantibodies are less frequently detected by ELISA, 
but they response to other epitopes of BP180. Clinical outcome is similar such as in 
classical non-DPP-4 BP patients, regardless of withdrawal of DPP-4 inhibitors.
Keywords: bullous pemphigoid, noninflammatory, dipeptidyl peptidase-4 inhibitor, 
gliptins, eosinophil
1. Introduction
Bullous pemphigoid (BP) is a rare autoimmune blistering disease of elderly 
patients, but in the last decades, it shows increasing incidence [1–8]. Higher preva-
lence of BP may be according to the increasing global life expectancy of the popula-
tion, increasing incidence of predisposing neurological diseases, growing numbers 
of provoking drugs, and improving awareness of newly recognized atypical clinical 
phenotypes and better diagnostic methods [1]. The role of culprit drugs such as 
neuroleptics, diuretics, and antidiabetics is reported in several studies [1, 2, 9]. BP 
is typically present in elderly with a higher predominance in female patients [4, 7]. 
The classical clinical features of BP are generalized bullous skin eruptions with sur-
rounding erythema and itching; peripheral eosinophilia is also common. Mucosal 
involvement was observed in 10–30% of patients [2]. Atypical clinical variants may 
be present up to 20% in BP, including the more common prurigo-like or urticarial 
type, eczema-like type, dyshidrosiform type, erosive type, and erythema annulare 
centrifugum-like phenotype [1, 7]. The diagnosis is based on the histological 
findings, including direct and indirect immunofluorescence microscopy and 
anti-BP180/BP230 enzyme-linked immunosorbent assays (ELISA) [2]. The gold 
standard for the treatment of the disease according to guidelines is corticosteroid, 
in topical or systemic administration and in severe cases with adjuvant immuno-
suppressive medications, such as azathioprine, methotrexate, or mycophenolate 
mofetil [2]. In the case of drug-induced BP, the most important therapeutic step is 
the withdrawal of the culprit drug [9].
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2. Bullous pemphigoid and diabetes
BP is a chronic, relapsing disease in patients with several comorbidities and 
significant morbidity. Investigating the prevalence of diabetes mellitus (DM) in BP, 
a higher frequency of DM has been found in the last decade [10, 11]. In accordance 
to several case reports [12–18], case series, case-control studies, pharmacovigilance 
reports, and retrospective investigations [19–37], the growing number of DM in BP 
patients is in association with the increasing use of an antidiabetic drug, the dipep-
tidyl peptidase-4 inhibitor (DPP-4i). DPP-4i, also called gliptins, was approved in 
2006 to treat type 2 DM. Sitagliptin, vildagliptin, linagliptin, saxagliptin, and alo-
gliptin have been approved by FDA or EMA; anagliptin, trelagliptin, omarigliptin, 
and teneligliptin have approval only in Japan. Gliptins are used in monotherapy or 
in combination with metformin. However, there is a clear evidence of provoking 
role of DPP-4 inhibitors in BP; the pathomechanism of it is still not understood.
3. Demographics of DPP-4 inhibitor-related BP
DPP-4 inhibitor intake was associated with a threefold increased risk for BP [27, 31, 38].  
According to the former investigations [14, 23, 26, 27, 29, 31, 38, 39], vildagliptin has 
the strongest association with BP; the risk was tenfold (ranged between 7.23 and 11.8) 
in a systemic review and meta-analysis by Kridin et al. [38]. A higher, sixfold risk 
was also observed with linagliptin [27, 38]. Higher risk of DPP-4i-BP was also found 
with sitagliptin by Lee et al. [40], and they also found in a larger sample size (patients 
with DPP-4i-BP n = 260) that the risks associated with specific DPP-4 inhibitors were 
lower than the previous studies [27, 38], 1.81 for vildagliptin, 1.64 for linagliptin, and 
1.7 for sitagliptin. However, a significant association was detected with vildagliptin, 
linagliptin, and sitagliptin in age- and sex-matched controlled population; the associa-
tion with saxagliptin in BP was not significant [27, 31]. Saxagliptin, anagliptin- and 
alogliptin-induced BP were presented only in a few sporadic cases [29, 31, 32, 40, 41]. 
DPP-4 inhibitors are often given in combination with metformin; the two recent pub-
lications reported that the association of BP and gliptins is independent of metformin 
exposure [27, 30]. Despite the BP is more common in females, a multicenter investiga-
tion and EudraVigilance data showed that DPP-4 inhibitor-associated BP tends to be 
more common in men [14, 23], similarly to Kridin et al. [27] and Lee et al. [40] and 
in contrast to Varpuluoma et al., who found a higher risk for BP in women taking 
DPP-4 inhibitors [30]. The mean age of DPP-4i-related BP patients ranged between 
76.6 and 79.1 years [23, 27, 39]. Kridin et al. presented the strongest association in 
patients younger than 70 years [27], while Benzaquen et al. found stronger association 
in patients older than 80 years [23], while Lee et al. observed 1.76-fold risk in patients 
younger than 75 years and 1.5-fold risk in patients older than 75 years [40]. The mean 
latency period between the initiation of gliptin and the appearance of BP is ranging 
from 6 to 26.4 months  
[23, 27, 29, 30, 33]. That means DPP-4 inhibitors can be suspected in the pathogenesis 
of BP if the drug has been initiated at least 6 months, but it also has to be considered if 
the drug intake last for more than 2 years prior to the onset of BP.
4. Clinical features of DPP-4 inhibitors-related noninflammatory BP
The classical clinical picture of BP is generalized as bullous skin lesions, tense blis-
ters with severe urticarial erythema. Recent publications characterized a noninflam-
matory form of BP with limited distribution, smaller blisters, and scant erythema 
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(Figures 1 and 2) [37, 42, 43]. These noninflammatory phenotypes do not react with 
the NC16A domain of BP, show better clinical outcome, and has a higher prevalence 
in DPP-4 inhibitor taking patients [22, 32, 34–37, 42, 43]. Noninflammatory BP can 
Figure 1. 
DPP-4i-related bullous pemphigoid. Mild skin involvement localized to the upper part of the trunk with small 
blisters and erosions without erythema in a male patient.
Figure 2. 
DPP-4i-related bullous pemphigoid in a female patient with small, round erosions without 
erythema on the upper extremities.
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also be found in non-DPP-4-related cases but in a significantly lower manner. Higher 
frequency of mucosal involvement was reported in gliptin-associated BP in two 
studies (Kridin et al., 22.2%, n = 36, and Chijiwa et al., 78%, n = 9) [27, 33], but this 
observation was not supported by Plaquevent (n = 108) [31]. Interestingly, in gliptin-
associated mucous membrane pemphigoid (MMP) there is a significantly lower buc-
cal and more common cutaneous involvement [44]. Previous studies demonstrated 
that eosinophil count is in correlation with the severity of BP [45–47] and with BPDAI 
score [46]. Comparing the Bullous Pemphigoid Disease Area Index (BPDAI) [48], 
BPDAI scores for urticaria/erythema (U/E) were significantly lower in noninflam-
matory phenotypes [33, 36, 42, 43], and lower BPDAI U/E was in correlation with 
decreased eosinophil count in the perilesional skin [33, 42]. Significantly decreased 
peripheral eosinophil count was detected in patients of Kridin et al. [27].
5. Immunological characterization of DPP-4 inhibitor-related BP
In BP, there are two targets for autoantibodies, the hemidesmosomal BP180 
and BP230 and the juxtamembranous extracellular non-collagenous 16A 
(NC16A), both of them can be easily detected by commercially available ELISA 
tests [2, 49, 50]. The domain of BP180 (also called COL17) is a major target 
epitope in 80–90% of cases [49]. In several investigations, noninflammatory BP 
patients did not show reactivity against the NC16A domain of BP180, but they 
were positive for full-length BP180 and its ectodomain midportion with ELISA 
[34, 36, 42]. The midportion of BP180 is more likely to be recognized than the 
NC16A domain in DPP-4i-associated noninflammatory BP patients; they are pre-
sented with localized symptoms and mild erythema [32, 35, 36, 42, 51]. Although 
there was a positive reaction to anti-NC16A in DPP-4i-BP cases, but they were 
mainly presented with prominent erythema and inflammation, concurring with 
classical phenotype of BP [31, 35, 42]. Kawaguchi et al. showed that the rate of 
ELISA positivity and antibody titers for anti-BP180 NC16A was significantly 
lower in DPP-4i-BP than the non-DPP-4 group [22], and this lower titer was also 
observed by García-Díez et al. [52]. Kawaguchi has also emphasized that patients 
with DPP-4i-BP tended to have noninflammatory phenotype of BP and presented 
with negative ELISA for BP180 NC16A domain [22]. Some studies reported 
noninflammatory DPP-4-induced BP patients who were negative for anti-NC16A 
domain initially but responded to the full-length BP180 and became positive for 
NC16A during the course of the disease. This epitope spreading was observed in 
several cases, after the prolonged use of DPP-4 inhibitors after the onset of BP  
[17, 37, 52]. Other investigations also demonstrated that multiple epitopes of 
BP180 are targeted in DPP-4i-BP (midportion, C terminus, and LAD1) [35, 52], 
and it may suggest that epitope spreading is more common in DPP-4i-BP than 
in classical BP cases [35]. García-Díez et al. suggested the major role of the 
midportion of BP180 in DPP-4i-BP, while other BP180 regions are involved later 
by epitope spreading [52]. Indirect IF positivity was also detected in DPP-4i-BP 
patients [13, 27, 34], and anti-BP230 autoantibodies were present [34, 35], but the 
sensitivity of the test was only 38%, which is lower than usually reported [51].
6. Clinical outcome
Based on several investigations, withdrawal of the DPP-4 inhibitors was the first 
therapeutic step in most cases in the treatment of the disease [23, 34]. Regarding 
to these data, discontinuation of DPP-4i treatment seems to have a favorable 
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impact on the clinical outcome of BP [23, 27, 34], but Plaquevent et al. have found 
that there is no difference in outcome in patients who have further got the gliptin 
treatment after the diagnosis of BP [31]. Regardless of DPP-4 inhibitor withdrawal, 
standard treatment protocol was applied in most cases, topical potent corticosteroid 
treatment in localized form and gold standard systemic corticosteroid treatment 
with adjuvant immunosuppressive therapy, such as azathioprine, mycophenolate 
mofetil, or methotrexate in severe cases [27, 31]. Relapse rates were similar in DPP-
4i-BP patients such it was previously reported [31].
7. Conclusions
Dipeptidyl peptidase-4 inhibitors (also called gliptins) are widely used drug 
in the treatment of type 2 diabetes mellitus. There is an increased risk of BP in 
patients during DPP-4 inhibitor treatment. The exact pathomechanism of DPP-
4i-associated BP is still unclear. Dipeptidyl peptidase 4 (also called CD26) is a 
110 kDa transmembrane glycoprotein, which is expressed on the surface of several 
cells, such as T cells [53, 54]. DPP-4 has antihyperglycemic effect and enzymatic 
activity; it plays a major role in glucose metabolism by blocking incretin [54]. 
DPP-4 is a plasminogen receptor that activates plasminogen resulted in plasmin 
formation [55, 56]. Plasmin, a serine protease, which has a high level in lesional 
skin and in blister fluid in BP [57], cleaves BP180 within the NC16A domain [58]. 
Cleavage of BP180 in the NC16A region can induce neoepitopes with altered anti-
genicities [42, 59]. The antifibrotic effect of DPP-4 inhibitors in the skin also sup-
ports the role of DPP-4 in collagen metabolism [56]. DPP-4 is involved in immune 
cell activation, and its inhibition can modify the immune response, which may 
increase the activation of eosinophil recruitment into the dermis, which is consid-
ered to be essential in blister formation in BP [60]. In contrary to these findings, 
in patients with gliptin-associated noninflammatory BP, both peripheral and 
perilesional skin eosinophil counts are significantly lower than in classical BP 
[27, 33], so the exact pathognostic role of eosinophils in DPP-4-related BP needs 
further investigations. It is also not elucidated why vildagliptin has the strongest 
association with BP, but it is known that vildagliptin has the lowest selectivity 
among gliptins with strong inhibition of DDP8 and DPP9 isozymes [22, 61]. 
Some results suggest that DPP-4 inhibitor has immunomodifier effect mainly in 
Table 1. 
Comparison of clinical features in DPP-4i-related and classical type bullous pemphigoid.
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of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
genetically susceptible individuals, and they have detected that HLA-DQB1*03:01 
allele has higher prevalence in DPP-4i-BP patients [22, 62].
In conclusion, DPP-4 inhibitor-related BP tends to be presented with noninflam-
matory phenotype of BP, with limited extension, smaller blisters, scant perilesional 
erythema and eosinophilic infiltration, and normal or slightly elevated peripheral 
eosinophil count (Table 1). Anti-NC16A BP180 positivity is less common, and ELISA 
titers are slightly elevated, similarly to anti-BP230, but positivity for full-length BP180 
or other epitopes of BP180 may be detected. Response to therapy is similar such as in 
classical non-DPP-4i-BP patients, regardless of withdrawal of DPP-4 inhibitors.
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